Category Archives: Prevention, Engagement and Care Cascade

Sexually transmitted and blood-borne infections in transgender and non-binary people in Canada: A scoping review

2025

In the 2021 census, 100,815 people in Canada aged 15 and older identified as transgender or non-binary. Globally, transgender people are disproportionately burdened by several Sexually Transmitted and Blood-Borne Infections...

Knowledge, attitudes, and willingness of healthcare workers to offer pre-exposure prophylaxis in Africa: A systematic review and meta-analysis

2025

Background Despite advancements in HIV prevention strategies, including pre-exposure prophylaxis (PrEP), uptake remains suboptimal in high-burden regions like Africa. Healthcare workers (HCWs) play a pivotal role in PrEP implementation. This...

Morbidity and mortality risk among people with HIV and central or visceral adiposity: A targeted literature review

2025

BACKGROUND: Given the known relationship between human immunodeficiency virus (HIV), antiretroviral therapies, and excess visceral adipose tissue (VAT), this review sought to characterize risk of negative health outcomes associated with...

Mental health interventions for young pepole living with HIV/AIDS in sub-Saharan Africa: A systematic review

2025

Introduction: Young people (aged 15-24) living with HIV/AIDS (YPLHIV) in sub-Saharan Africa (SSA) experience higher rates of mental health conditions compared to their uninfected peers. Research and practitioners have expressed...

Effects of test-and-treat versus preexposure prophylaxis on elimination of HIV transmission: Analysis of 24 HIV prevention trials

2025

INTRODUCTION: In 2023, 28.8 million (72%) of 39.9 million people with HIV (PWH) worldwide were on treatment with viral suppression, while 11.1 million (28%) people had viraemia with the risk...

Characterizing the HIV care continuum among children and adolescents with HIV in eastern and southern Africa in the era of “Universal Test and Treat”: A systematic review and meta-analysis

2025

INTRODUCTION: The “Universal Test and Treat” (UTT) era for antiretroviral therapy (ART) increased HIV service delivery to children and adolescents aged 0-19 with HIV. The goal is to reach ƒ%95%...

Free antiretrovirals as a key tool against the HIV pandemic: A systematic review

2025

BACKGROUND/OBJECTIVES: Access to antiretroviral (ARV) drugs remains a critical challenge in achieving the WHO/UNAIDS 95-95-95 targets, with medication costs representing a substantial barrier. This systematic review evaluates the effect of...

Interventions integrating mental health services into HIV care in Africa; A scoping review

2025

OBJECTIVES: This scoping review aims to synthesize existing evidence on mental health (MH) interventions for people living with HIV/AIDS (PLWHA) in Africa. Given the high prevalence of MH disorders in...

Cabotegravir plus rilpivirine injection for virally suppressed persons with HIV-1 infection: A systematic review and meta-analysis of randomized controlled trials

2025

Purpose: This study evaluated the efficacy and safety of cabotegravir/rilpivirine long-acting formulation compared to oral standard of care at 48 and 52 weeks. Method: We conducted an electronic search (2005-2024) across databases...

Pharmacokinetic adaptations in pregnancy: Implications for optimizing antiretroviral therapy in HIV-positive women

2025

Pregnancy introduces significant physiological changes that alter the pharmacokinetics (PK) of antiretroviral therapy (ART), impacting its safety and efficacy in HIV-positive women. Optimizing ART during pregnancy is critical to maintaining...

Cannabis use and HIV among Black sexually minoritized men: A systematic review and narrative analysis

2025

Objective: We conducted a systematic review evaluating the extant literature examining the impacts of cannabis use on HIV-related outcomes among Black sexual minoritized men (BSMM). Design: A systematic review. Methods: We conducted a...

Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-naïve people with HIV-1: A systematic literature review and network meta-analysis

2025

Aim: Bictegravir, emtricitabine and tenofovir alafenamide (B/F/TAF) is a single-tablet regimen approved for the treatment of HIV-1 in treatment-naive (TN) and virologically suppressed people with HIV-1 (PWH). While the efficacy of...

Email 1 selected articles

Email 1 selected articles

Error! The email wasn't sent. Please try again.

Your email has been sent!